PNEUMOVAX * 23 (Pneumococcal Vaccine Polyvalent) is a sterile, liquid vaccine for intramuscular or subcutaneous injection. It consists of a mixture of highly purified capsular polysaccharides from the 23 most prevalent or invasive pneumococcal types of
including the six serotypes that most frequently cause invasive drug-resistant pneumococcal infections among children and adults in the United States. (See Table 1.) The 23-valent vaccine accounts for at least 90% of pneumococcal blood isolates and at least 85% of all pneumococcal isolates from sites which are generally sterile as determined by ongoing surveillance of U.S. data.
PNEUMOVAX 23 is indicated for vaccination against pneumococcal disease caused by those pneumococcal types included in the vaccine.
Published Studies Related to Pneumovax (Pneumococcal Vaccine Polyvalent)
Effect of pneumococcal Haemophilus influenzae protein D conjugate vaccine
(PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster
randomised phase 3-4 trial. 
antimicrobial purchases... INTERPRETATION: Despite low relative rate reductions the absolute rate reductions
Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D
conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster
randomised trial. 
invasive pneumococcal disease... INTERPRETATION: This nationwide trial showed high PHiD-CV10 effectiveness against
Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal
conjugate vaccines in reducing nasopharyngeal colonization: a randomized
double-blind trial. 
clinical endpoints... CONCLUSIONS: PCV13 resulted in lower acquisition and prevalence of NP
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults
70 years of age and older previously vaccinated with 23-valent pneumococcal
polysaccharide vaccine. 
conjugate vaccine (PCV13)... CONCLUSION: In adults aged 70 years and older previously vaccinated with PPSV23,
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in
healthy infants and toddlers given with routine vaccines in India. 
double-blind trial conducted at 12 sites in India... CONCLUSIONS: PCV13 has immunogenicity similar to PCV7 in response to the 7 common
Clinical Trials Related to Pneumovax (Pneumococcal Vaccine Polyvalent)
Study Evaluating Antibody Response of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children Previously Given PnC [Recruiting]
This is an open-label study (a study in which the doctors and participants know which drug
or vaccine is being administered) in children who previously received a 4-dose series of a
pneumococcal conjugate vaccine (PnC) during infancy in Study 6096A1-008-EU (NCT00366678).
In this study, participants will receive an additional dose of 13-valent pneumococcal
conjugate vaccine. The purpose of this study is to evaluate persistence, if any, of the
antibody response by measuring any remaining pneumococcal antibodies since the previous
study. This study will also evaluate the safety and immunogenicity of 13-valent
pneumococcal conjugate vaccine when administered at least 24 months after the last dose of
pneumococcal conjugate vaccine.
A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria [Recruiting]
A vaccine called Prevenar is already approved for use in China for vaccination of children
younger than 6 years old against infections caused by Streptococcus pneumoniae.
This study is to measure the amount of antibodies (antibodies help people fight off
diseases) Chinese children aged between 121 days and 6 years (72 months) produce when given
Prevenar. The study will also provide more data on how safe and well tolerated Prevenar is
in Chinese children.
Pneumococcal Conjugate Vaccine Followup [Recruiting]
Recently, controversy has emerged regarding the role of the 23vPPV in infants due to
potential immunological hypo-responsiveness (i. e. a poorer immune response to repeat
vaccination). Although previous experience of 23vPPV in children in PNG has demonstrated
protective efficacy against acute lower respiratory tract infection, the investigators feel
it is a matter of urgency to determine if 23vPPV administration provides elevated antibody
concentrations at 3 to 5 years of age, and to ensure the immunological safety of the 23vPPV
Following consent and eligibility assessment, a baseline blood sample and nose swab will be
taken, a 0. 1ml dose of 23vPPV will be administered and a follow up blood sample and nose
swab will be collected 28 days later. The investigators will also collect data on incidence
of ALRI in all study participants by medical record review.
Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine [Recruiting]
The study will evaluate the safety, tolerability and immunogenicity of a 13-valent
pneumococcal conjugate vaccine (13vPnC) in HIV-infected subjects 6 years of age or older who
have not been previously immunized with a pneumococcal vaccine. All subjects will receive 3
doses of 13vPnC and 1 dose of 23-valent pneumococcal polysaccharide vaccine (23vPS), with
each dose given approximately 1 month apart.
Study Assessing the Effect of Medications to Prevent Fever on Prevenar 13� [Not yet recruiting]
The purposes of this study are assess the immunological response (measure the amount of
antibodies, i. e. proteins that fight off germs) produced by children after they have been
given the 13-valent pneumococcal vaccine (13vPnC) and INFANRIX hexa at 2, 3, 4 and 12 months
of age when medications to prevent fever are given on the same day as the vaccination. Also
to evaluate the safety of 13-valent pneumococcal conjugate vaccine (13vPnC) in children who
receive medications to prevent fever on the day of vaccination.